Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares Biotech Investing
ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872 Pharmaceutical Investing
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients Pharmaceutical Investing
Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura Pharmaceutical Investing
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
